ClinicalTrials.gg
CompletedNCT00736190Updated Dec 5, 2011Results posted

A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection

A Phase 4 interventional study of Tenofovir disoproxil fumarate in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 21 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-12-05.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.

Enrollment
34th of 50
90 · median 117
Started
2008
with 6 others
Phase 4
22 of 50
none open now
Registered
10th of 50
by date
Lead sponsor
8 of 50
Gilead Sciences

Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 34th largest by enrollment, is one of 7 that started in 2008, is one of 22 in phase 4, and was the 10th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing tenofovir in Hepatitis B, Chronic as a file.
02

Study summary

The purpose of this study is to evaluate the antiviral activity and safety of tenofovir disoproxil fumarate (TDF) in Asian-American adults (self-reported Asian descent, living in the United States) with chronic hepatitis B infection. All participants will receive active treatment with TDF for 48 weeks.

Read the detailed description

Efficacy of TDF will be evaluated for reductions in serum HBV DNA, changes in liver enzymes, and the generation of antibody to the virus. Safety will be assessed by evaluating adverse events, laboratory abnormalities, and the development of drug resistance mutations.

03

Conditions studied

  • Chronic Hepatitis B

Keywords

  • Hepatitis B
  • Hepatitis
  • Tenofovir disoproxil fumarate
  • Tenofovir DF
  • Asian-American
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Asian-American, defined as a person of self-reported Asian ancestry who is residing in the United States (US)
  • 18 through 75 years of age, inclusive
  • Documented chronic infection, defined as positive serum HBsAg =/> 6 months
  • HBV DNA =/> 10,000 copies/mL (PCR method)
  • > and \</= 10 × ULN at screening or within the past 12 months prior to screening
  • Willing and able to provide written
  • Negative serum beta-human chorionic gonadotropin (HCG) pregnancy test (females of )
  • Estimated () =/> 60 mL/min/1.73m\^2 by the Cockcroft-Gault equation
  • Adequate hematologic function ( =/> 1,500/mm\^3; =/> 10.0 g/dL)
  • No prior TDF therapy; participants may have taken \< 12 weeks of oral anti-HBV therapy, with the last dose =/> 16 weeks prior to screening; participants may have received prior interferon, but must have discontinued interferon therapy =/> 6 months prior to screening

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following exclusion criteria are not to be enrolled in this study.

  • Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study.
  • Males and females of who are not willing to use an effective method of during the study. For males, condoms should be used and for females, a barrier contraception method should be used in combination with one other form of contraception.
  • Decompensated liver disease defined as direct (conjugated) > 1.2 X , (PT) > 1.2 X ULN, \< 150,000/mm3, or serum albumin \< 3.5 g/dL
  • Prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy) or variceal hemorrhage
  • Receipt of prior TDF treatment
  • Receipt of =/> 12 weeks of oral anti- nucleoside/nucleotide therapy, or receipt of ANY oral anti-HBV treatment \< 16 weeks prior to screening
  • Receipt of interferon (pegylated or not) therapy within 6 months of the Screening Visit
  • alpha-fetoprotein > 50 ng/mL
  • Evidence of hepatocellular carcinoma (HCC)
  • Co-infection with (HIV), virus (HCV), or hepatitis D virus (HDV)
  • History of significant renal disease (eg, nephrotic syndrome, renal dysgenesis, polycystic kidney disease, congenital nephrosis, acute tubular necrosis, other renal disease)
  • History of significant bone disease (eg, osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, osteochrondroses, multiple bone fractures)
  • Significant cardiovascular, pulmonary or neurological disease
  • Evidence of a gastrointestinal malabsorption syndrome that may interfere with absorption of orally administered medications
  • History of solid organ or bone marrow transplantation
  • Ongoing therapy with any of the following: nephrotoxic agents, competitors of renal excretion (eg, probenecid), systemic chemotherapeutic agents, systemic , Interleukin-2 (IL-2) and other immunomodulating agents, agents (except with the expressed approval of the Sponsor); administration of any of the above medications must be discontinued at least 30 days prior to the Baseline Visit and for the duration of the study period
  • Known to the study drugs, the metabolites, or formulation
  • Any other condition (including alcohol or substance abuse) or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    TDF

    300-mg tablet (marketed formulation) taken orally once daily

    Drug: Tenofovir disoproxil fumarate

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/mL (<69 IU/mL)

    Blood samples were collected from study participants for measuring HBV DNA via polymerase chain reaction (PCR) method.

    Time frame: Week 48

Secondary outcomes

  1. Number of Participants With Alanine Aminotransferase (ALT) Normal at Week 48

    Number of participants with normal ALT (at or below the upper limit of normal \[ULN\] for the central laboratory \[34 U/L\])at Week 48

    Time frame: Week 48

  2. Number of Participants With ALT Normalized (Baseline Values > ULN [34 U/L] and <= ULN at a Subsequent Visit) at Week 48

    A normal value at Week 48 after having elevated ALT at baseline; normal ALT is defined as being at or below the ULN for the central laboratory (34 U/L)

    Time frame: Week 48

  3. Number of Participants With Composite Endpoint of Hepatitis B Virus (HBV) DNA <400 Copies/mL (<69 IU/mL) and Normal ALT at Week 48

    Blood samples were collected for evaluating serum chemistry, including determination of ALT, and for measuring HBV DNA via PCR method. Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA \< 400 copies/mL (\<69 IU/mL) and normal ALT (ALT \<= ULN \[34 U/L\]); and with HBV DNA \< 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost hepatitis B e antigen (HBeAg) or developed antibody to hepatitis B e antigen (anti-HBe), only the composite endpoint of HBV DNA \< 400 copies/mL and normal ALT was analyzed.

    Time frame: Week 48

  4. Change From Baseline in FibroTest Value

    The FibroTest score is used to assess liver fibrosis and is calculated based on a formula including the participant's age and sex and 5 laboratory parameters: alpha 2 macroglobulin, haptoglobin, gamma-glutamyl transferase (GGT), bilirubin, and apolipoprotein A1. Scores can range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.

    Time frame: Baseline and Week 48

  5. Number of Participants With HBeAg/Hepatitis B Surface Antigen (HBsAg) Loss and Seroconversion

    HBeAg/HBsAg loss is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- at Week 48. HBeAg/HBsAg serocoversion is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- and anti-HBe+/antibody to hepatitis B surface antigen+ (anti-HBs+) at Week 48.

    Time frame: Week 48

  6. Number of Participants With HBV DNA < 169 Copies/mL (<29 IU/mL) at Week 48

    Blood samples from study participants were collected for measuring HBV DNA via PCR method.

    Time frame: Week 48

  7. Number of Participants With Composite Endpoint of HBV DNA <400 Copies/mL (<69 IU/mL), Normal ALT, and HBeAg Loss

    Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA \< 400 copies/mL (\<69 IU/mL) and normal ALT (ALT \<= ULN \[34 U/L\]); and with HBV DNA \< 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost HBeAg or seroconverted to anti-HBe, only the composite endpoint of HBV DNA \< 400 copies/mL and normal ALT was analyzed.

    Time frame: Week 48

  8. Number of Participants With Composite Endpoint of HBV DNA <400 Copies/mL (<69 IU/mL), Normal ALT, and Seroconversion to Anti-HBe

    Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA \< 400 copies/mL (\<69 IU/mL) and normal ALT (ALT \<= ULN); and with HBV DNA \< 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost HBeAg or seroconverted to anti-HBe, only the composite endpoint of HBV DNA \< 400 copies/mL and normal ALT was analyzed.

    Time frame: Week 48

  9. Summary of Resistance Surveillance for Participants Without Virologic Breakthrough

    Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.

    Time frame: Week 48

  10. Summary of Resistance Surveillance for Participants With Virologic Breakthrough

    Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.

    Time frame: Week 48

  11. Summary of Resistance Surveillance for Participants Who Discontinued the Study Early

    Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.

    Time frame: Week 48

07

Results

Posted Aug 3, 2011

Participant flow

Participant flow — Overall Study
MilestoneA: TDF
Started90
Completed87
Not completed3
Withdrew: Pregnancy1
Withdrew: Withdrawal by subject1
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/mL (<69 IU/mL)

Blood samples were collected from study participants for measuring HBV DNA via polymerase chain reaction (PCR) method.

Time frame:
Week 48
Reported as:
Number · Participants
Number of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/mL (<69 IU/mL)
ParticipantsTenofovir DF
Number of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/mL (<69 IU/mL)74
SecondaryNumber of Participants With Alanine Aminotransferase (ALT) Normal at Week 48

Number of participants with normal ALT (at or below the upper limit of normal \[ULN\] for the central laboratory \[34 U/L\])at Week 48

Time frame:
Week 48
Reported as:
Number · Participants
Number of Participants With Alanine Aminotransferase (ALT) Normal at Week 48
ParticipantsTenofovir DF
Number of Participants With Alanine Aminotransferase (ALT) Normal at Week 4859
SecondaryNumber of Participants With ALT Normalized (Baseline Values > ULN [34 U/L] and <= ULN at a Subsequent Visit) at Week 48

A normal value at Week 48 after having elevated ALT at baseline; normal ALT is defined as being at or below the ULN for the central laboratory (34 U/L)

Time frame:
Week 48
Reported as:
Number · participants
Number of Participants With ALT Normalized (Baseline Values > ULN [34 U/L] and <= ULN at a Subsequent Visit) at Week 48
participantsTenofovir DF
Number of Participants With ALT Normalized (Baseline Values > ULN [34 U/L] and <= ULN at a Subsequent Visit) at Week 4840
SecondaryNumber of Participants With Composite Endpoint of Hepatitis B Virus (HBV) DNA <400 Copies/mL (<69 IU/mL) and Normal ALT at Week 48

Blood samples were collected for evaluating serum chemistry, including determination of ALT, and for measuring HBV DNA via PCR method. Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA \< 400 copies/mL (\<69 IU/mL) and normal ALT (ALT \<= ULN \[34 U/L\]); and with HBV DNA \< 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost hepatitis B e antigen (HBeAg) or developed antibody to hepatitis B e antigen (anti-HBe), only the composite endpoint of HBV DNA \< 400 copies/mL and normal ALT was analyzed.

Time frame:
Week 48
Reported as:
Number · Participants
Number of Participants With Composite Endpoint of Hepatitis B Virus (HBV) DNA <400 Copies/mL (<69 IU/mL) and Normal ALT at Week 48
ParticipantsTenofovir DF
Number of Participants With Composite Endpoint of Hepatitis B Virus (HBV) DNA <400 Copies/mL (<69 IU/mL) and Normal ALT at Week 4855
SecondaryChange From Baseline in FibroTest Value

The FibroTest score is used to assess liver fibrosis and is calculated based on a formula including the participant's age and sex and 5 laboratory parameters: alpha 2 macroglobulin, haptoglobin, gamma-glutamyl transferase (GGT), bilirubin, and apolipoprotein A1. Scores can range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.

Time frame:
Baseline and Week 48
Reported as:
Mean · Scores on a scale
Change From Baseline in FibroTest Value
Scores on a scaleTenofovir DF
Change From Baseline in FibroTest Value-0.006 ± 0.1024
SecondaryNumber of Participants With HBeAg/Hepatitis B Surface Antigen (HBsAg) Loss and Seroconversion

HBeAg/HBsAg loss is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- at Week 48. HBeAg/HBsAg serocoversion is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- and anti-HBe+/antibody to hepatitis B surface antigen+ (anti-HBs+) at Week 48.

Time frame:
Week 48
Reported as:
Number · Participants
Number of Participants With HBeAg/Hepatitis B Surface Antigen (HBsAg) Loss and Seroconversion
ParticipantsTenofovir DF
HBsAg+ at baseline90
HBsAg- at baseline0
HBsAg+ at Week 4888
HBsAg data missing at Week 482
HBeAg+ at baseline53
HBeAg- at baseline37
HBeAg loss by Week 486
Anti-HBe+ seroconversion by Week 486
SecondaryNumber of Participants With HBV DNA < 169 Copies/mL (<29 IU/mL) at Week 48

Blood samples from study participants were collected for measuring HBV DNA via PCR method.

Time frame:
Week 48
Reported as:
Number · Participants
Number of Participants With HBV DNA < 169 Copies/mL (<29 IU/mL) at Week 48
ParticipantsTenofovir DF
Number of Participants With HBV DNA < 169 Copies/mL (<29 IU/mL) at Week 4873
SecondaryNumber of Participants With Composite Endpoint of HBV DNA <400 Copies/mL (<69 IU/mL), Normal ALT, and HBeAg Loss

Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA \< 400 copies/mL (\<69 IU/mL) and normal ALT (ALT \<= ULN \[34 U/L\]); and with HBV DNA \< 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost HBeAg or seroconverted to anti-HBe, only the composite endpoint of HBV DNA \< 400 copies/mL and normal ALT was analyzed.

Time frame:
Week 48
Reported as:
Number · Participants

Results for this outcome have not been posted.

SecondaryNumber of Participants With Composite Endpoint of HBV DNA <400 Copies/mL (<69 IU/mL), Normal ALT, and Seroconversion to Anti-HBe

Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA \< 400 copies/mL (\<69 IU/mL) and normal ALT (ALT \<= ULN); and with HBV DNA \< 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost HBeAg or seroconverted to anti-HBe, only the composite endpoint of HBV DNA \< 400 copies/mL and normal ALT was analyzed.

Time frame:
Week 48
Reported as:
Participants

Results for this outcome have not been posted.

SecondarySummary of Resistance Surveillance for Participants Without Virologic Breakthrough

Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.

Time frame:
Week 48
Reported as:
Number · Participants
Summary of Resistance Surveillance for Participants Without Virologic Breakthrough
ParticipantsTenofovir DF
No changes in HBV pol/RT6
Changes at polymorphic sites1
Changes at conserved sites2
Unable to genotype1
SecondarySummary of Resistance Surveillance for Participants With Virologic Breakthrough

Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.

Time frame:
Week 48
Reported as:
Number · Participants
Summary of Resistance Surveillance for Participants With Virologic Breakthrough
ParticipantsTenofovir DF
No changes in HBV pol/RT2
Changes at polymorphic sites0
Changes at conserved sites0
Unable to genotype0
SecondarySummary of Resistance Surveillance for Participants Who Discontinued the Study Early

Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.

Time frame:
Week 48
Reported as:
Number · Participants
Summary of Resistance Surveillance for Participants Who Discontinued the Study Early
ParticipantsTenofovir DF
No changes in HBV pol/RT1
Changes at polymorphic sites0
Changes at conserved sites0
Unable to genotype1

Adverse events

Collected over 48 weeks + the follow-up off-study medication period (if applicable). Participants who permanently discontinued study drug were to be followed for 24 weeks off treatment or up to initiation of active treatment, whichever occurred first.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A: TDF—1/90 (1.1%)27/90 (30%)
Most frequent serious events
Most frequent serious events
EventA: TDF
Hepatic neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/90
Most frequent other events
Most frequent other events
EventA: TDF
NasopharyngitisInfections and infestations6/90
HeadacheNervous system disorders6/90
NauseaGastrointestinal disorders5/90
Weight decreasedInvestigations5/90
RashSkin and subcutaneous tissue disorders5/90

Baseline characteristics

Age Continuous
Age Continuous(years)A: TDF
Mean36.8 ± 10.49
Sex: Female, Male
Sex: Female, Male(Participants)A: TDF
Female43
Male47
Race (NIH/OMB)
Race (NIH/OMB)(Participants)A: TDF
American Indian or Alaska Native0
Asian90
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)A: TDF
United States90
Ethnicity
Ethnicity(Participants)A: TDF
Asian-Chinese58
Asian-Korean12
Asian-Vietnamese19
Asian-Cambodian1
Hepatitis B virus (HBV) deoxyribonucleic acid (DNA)
Hepatitis B virus (HBV) deoxyribonucleic acid (DNA)(log10 copies/mL)A: TDF
Mean7.484 ± 1.7678
Hepatitis B e antigen (HBeAg)
Hepatitis B e antigen (HBeAg)(Participants)A: TDF
Positive53
Negative37
Antibody to HBeAg (Anti-HBe)
Antibody to HBeAg (Anti-HBe)(Participants)A: TDF
Positive38
Unknown52

5 further baseline measures are reported on the registry.

08

Study locations

21 sites
  • Fountain Valley, California 92708, United States
  • Hacienda Heights, California 91745, United States
  • Los Angeles, California 90057, United States
  • Monterey Park, California 91754, United States
  • Mountain View, California 94040, United States
  • Oakland, California 94609, United States
  • Palo Alto, California 94304, United States
  • San Jose, California 95128, United States
  • Hamden, Connecticut 06518, United States
  • Baltimore, Maryland 21234, United States
  • Laurel, Maryland 20707, United States
  • Silver Spring, Maryland 20902, United States
  • Englewood, New Jersey 07631, United States
  • Brooklyn, New York 11219, United States
  • Flushing, New York 11355, United States
  • New York, New York 10013, United States
  • New York, New York 10038, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Fairfax, Virginia 22030, United States
  • Falls Church, Virginia 22044, United States
  • Bellevue, Washington 98004, United States
09

References and documents

Publications

  • Pan CQ, Chan S, Trinh H, Yao A, Bae H, Lou L. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. World J Gastroenterol. 2015 May 14;21(18):5524-31. doi: 10.3748/wjg.v21.i18.5524. PubMed 25987775 ↗
  • Pan CQ, Trinh H, Yao A, Bae H, Lou L, Chan S; Study 123 Group. Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings. PLoS One. 2014 Mar 4;9(3):e89789. doi: 10.1371/journal.pone.0089789. eCollection 2014. Erratum In: PLoS One. 2014;9(5):e98723. PubMed 24594870 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2008
First posted
Aug 15, 2008
Start
Aug 2008
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Aug 3, 2011
Last update
Dec 5, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00736190
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 15, 2008
Start date
Aug 2008
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Aug 3, 2011
Last update
Dec 5, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion